Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO -- Ignore unavailable to you. Want to Upgrade?

To: johnsto1 who wrote (17)	4/10/2000 8:07:00 AM
From: tom pope	Read Replies (1) \| Respond to of 368

There are three this week -Drugabuse Sciences (DASI) Exelixis (EXEL) and Genomic Solutions (GNSL). TheStreet.com's weekly ipo column notes that of the three bio ipo's last week, two were flat (incl SGMO) and was one down 15% - LEXG. An indication of how fast the sector fell out of favor. From the article: >>Weird week, last. 15 deals priced and traded to an average first-day gain of 43.61%. This number would have been much higher without factoring in the three biotechs that came to market. The average day-one performance for these three deals was -4.78%. In all fairness, the negative position of that number comes from one deal, Lexicon Genetics (LEXG:Nasdaq - news - boards), which finished its first day in the hole, down 14.77%. The other two were flat. It's official, bio-tech IPOs are dead. The heat last week came from technology -- networking, telecom, semiconductors and, my current favorite, software. My firm belief is that we will continue to see performance from these sectors in the months ahead. In the meantime, flashes of heat, like the one we saw in biotechs, will continue to appear and likely end as quickly as they began. My advice? Stick to the proven groups. <<